Autres langues Omeros Corporation

Actions

OMER

US6821431029

Temps réel estimé Cboe BZX Autres places de cotation 19:48:42 15/05/2024			Varia. 5j.	Varia. 1 janv.
4,145 ^USD	-1,31 %		+18,96 %	+28,42 %

01/04	Omeros Corporation (NasdaqGM:OMER) annonce un rachat d'actions pour une valeur de 50 millions de dollars.	CI
01/04	Omeros enregistre une perte nette au 4ème trimestre ; les perspectives pour le 1er trimestre sont fixées	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

OMEROS CORPORATION TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS ON MAY 15, 2024	13/05
OMEROS CORPORATION ANNOUNCES UPCOMING PRESENTATIONS AT 2024 EUROPEAN HEMATOLOGY ASSOCIATION HYBRID CONGRESS	10/05
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024	10/05
Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress	09/05
Tranche Update on Omeros Corporation's Equity Buyback Plan announced on April 1, 2024.	01/04
Omeros Corporation announces an Equity Buyback for $50 million worth of its shares.	01/04
Omeros Swings to Q4 Net Loss; Q1 Outlook Set	01/04
Omeros Corporation Provides Earnings Guidance for the First Quarter of 2024	01/04
Omeros Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Omeros: Q4 Earnings Snapshot	01/04
Omeros Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/04
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results	01/04
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024	27/03
North American Morning Briefing : Tech in Focus on -2-	25/03
North American Morning Briefing : Investors -2-	18/03
Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy	20/02
National Bank Raises DRI Healthcare Target to $22 on Omidria News, Guidance Increase	01/02
DRI Healthcare Trust Expands Royalty Entitlement on US Net Sales of Omidria, Updates Deployment and CAGR Guidance	01/02
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust	01/02
Omeros Corporation(NasdaqGM:OMER) dropped from NASDAQ Biotechnology Index	15/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Omeros Corporation

Actions

OMER

US6821431029

Autres langues

Filtres